Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Generating ectopic subcutaneous bone marrow by reconstitution of endochondral ossification

Hinako Notoh, Kanon Wada, Nobuaki Suzuki et al. Nov 03, 2025 pp. 1403-1403 10.1182/blood-2025-1403

Abstract 【Introduction】 Bone and marrow formation occur concurrently during endochondral ossification in most bones, e...

Ensuring equitable access to bispecific antibodies in multiple myeloma: Findings from the emmbrace patient and public involvement and engagement (PPIE) sessions.

Dunsi Bolarinwa, Rakesh Popat, Chantelle Hughes et al. Nov 03, 2025 pp. 6186-6186 10.1182/blood-2025-6186

Abstract Background: Bispecific antibodies (BsAbs) are effective treatments for relapsed/refractory multiple myeloma (RRMM), but uptake rema...

Targeting hells‑mediated chromatin accessibility to sensitize ALK‑negative anaplastic large cell lymphoma to JAK/STAT and DNA‑PK inhibition

Giulia Gambarelli, Selene Mallia, Benedetta Donati et al. Nov 03, 2025 pp. 1476-1476 10.1182/blood-2025-1476

Abstract Chromatin remodelers regulate DNA-nucleosome interactions, influencing chromatin structure, accessibility, and gene expression (Gou...

Impact of helicobacter pylori infection on clinical outcomes in patients with immune thrombocytopenia: A propensity-matched analysis from a national cohort

Jamil Nazzal, Mohammad Salameh, Zaid Zahid et al. Nov 03, 2025 pp. 4826-4826 10.1182/blood-2025-4826

Abstract Backgorund Over the past two decades, numerous international studies have explored a potential link between Hel...

Mapping genomic responses to kit receptor tyrosine kinase signaling in erythroid progenitors

Venkatasai Rahul Dogiparthi, Linda Chee, M Rowley et al. Nov 03, 2025 pp. 2882-2882 10.1182/blood-2025-2882

Abstract Chromatin signatures at cis-regulatory elements can predict how they regulate transcription. However, accurate cell type-specific p...

Favorable impact of patient's selection on outcome of Relapsed/Refractory multiple myeloma treated with idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy; Experience in french patients (Super-FENIX): An IFM study from the descar-T registry

Bertrand Arnulf, Jérôme Lambert, Lionel Karlin et al. Nov 03, 2025 pp. 4076-4076 10.1182/blood-2025-4076

Abstract Idecabtagene vicleucel (Ide-cel) is the first chimeric antigen receptor (CAR) T-cell therapy targeting the B-cell maturation antige...

Real-world study of treatment landscape and safety outcomes of US patients with blastic plasmacytoid dendritic cell neoplasm

Naveen Pemmaraju, Yangyang Liu, Amanda Kong et al. Nov 03, 2025 pp. 4605-4605 10.1182/blood-2025-4605

Abstract Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically aggressive hematological malignancy, with...

Results of the first Latin American point of care manufactured, Phase I anti- CD19 CAR-T study (CARTHIAE) for Relapsed/Refractory B-cell neoplasms

Lucila Kerbauy, Heitor Andrade, Mariana Kerbauy et al. Nov 03, 2025 pp. 2405-2405 10.1182/blood-2025-2405

Abstract Introduction: Chimeric Antigen Receptor (CAR) T-cell therapy targeting CD19 has demonstrated high efficacy in relapsed/refractory (...

Engineered biomimetic platelet membrane-coated nanoparticles as platelet decoys to reduce coagulopathy and improve outcomes in sepsis

Carly Carbery, Hasti Vatan Navaz, Elisabet Bjånes et al. Nov 03, 2025 pp. 423-423 10.1182/blood-2025-423

Abstract Introduction: Platelets (plt) play crucial roles not only in hemostasis but also in immune defense. Thrombocytopenia is common in s...

Lipid nanoparticle-mediated mRNA transfection enables efficient and safe generation of CAR macrophages.

Felix Chiu, Angela Hamie, Bee Tan et al. Nov 03, 2025 pp. 5918-5918 10.1182/blood-2025-5918

Abstract With the development of Chimeric Antigen Receptor (CAR) T-cells and its subsequent clinical trials and FDA approval, CAR T-cells ha...

Transcriptomic subclasses of KMT2A and NUP98 gene fusions in adolescent and adult Acute Myeloid Leukemia

Jianfeng Li, Wen-Yan Cheng, Yongmei Zhu et al. Nov 03, 2025 pp. 3475-3475 10.1182/blood-2025-3475

Abstract KMT2A and NUP98 gene fusions are two common types of acute myeloid leukemia (AML) with poor prognosis, incorporated as independent e...

Plek2 as a novel downstream effector of p53: Targeting Plek2 ameliorates disease progression in p53-deficient myeloid malignancies

Pan Wang, Xu Han, Honghao Bi et al. Nov 03, 2025 pp. 216-216 10.1182/blood-2025-216

Abstract TP53 mutations are common in myeloid malignancies and are associated with poor prognosis and therapeutic resistance. However, the d...

Eravacycline in allogeneic stem cell transplant recipients: A real-world study of drug-drug interactions with cyclosporine/tacrolimus and anti-infective efficacy

Jieya Luo, Xinhui Zheng, Xin Chen et al. Nov 03, 2025 pp. 7734-7734 10.1182/blood-2025-7734

Abstract Objective: Calcineurin inhibitors (CNIs) are standard prophylaxis for acute graft-versus-host disease (aGVHD) after allogeneic hema...

Disease-specific safety and efficacy of doacs vs. LMWH for venous thromboembolism in patients with brain metastases: A real-world trinetx analysis

Ali Mushtaq, Omer Ashruf, Mohanad Baroudi et al. Nov 03, 2025 pp. 1360-1360 10.1182/blood-2025-1360

Abstract Background: Determining the optimal anticoagulation strategy for venous thromboembolism (VTE) in patients with brain metastases rem...

Discrimination of Epstein–Barr virus latent infection and lytic replication reactivation using a novel methyl-CRISPR biosensor

Ting Wang, Guo-Ling Wang, Jingli Han et al. Nov 03, 2025 pp. 394-394 10.1182/blood-2025-394

Abstract Introduction: Epstein–Barr virus (EBV), the first identified human oncogenic gamma-herpesvirus, establishes lif...

Real-world poor prognostic impact of del(1p32) in newly diagnosed multiple myeloma among Asian populations

Ke Yuan, Yan Li, Wenjiao Tang et al. Nov 03, 2025 pp. 7514-7514 10.1182/blood-2025-7514

Abstract Background: Emerging evidence suggests that 1p32 deletion (del(1p32)) may represent an independent high-risk fa...

Prospective evaluation of venetoclax combined with CLAG regimen in relapsed/refractory acute myeloid leukemia: A multicenter, randomized controlled, open-lable, phase II Trial

Guopan Yu, Yu Zhang, Weihua Zhao et al. Nov 03, 2025 pp. 1000-1000 10.1182/blood-2025-1000

Abstract CLAG (cladribine + cytarabine + G-CSF) based regimen is recommended for the salvage treatment of relapsed/refractory (RR) acute mye...

Improved health-related quality of life (HRQoL) and bleeding scores with oral bruton tyrosine kinase (BTK) inhibitor rilzabrutinib in the open-label (OL) period of the multicenter Phase 3 LUNA3 study in adults with immune thrombocytopenia (ITP)

Nicola Cooper, Waleed Ghanima, Francesco Zaja et al. Nov 03, 2025 pp. 1254-1254 10.1182/blood-2025-1254

Abstract Introduction Rilzabrutinib, a BTK inhibitor that acts through multi-immune modulation, showed rapid and durable platelet response,...

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Keshu Zhou, Tingyu Wang, Ting Niu et al. Nov 03, 2025 pp. 88-88 10.1182/blood-2025-88

Abstract Introduction BCL-2 inhibitors play an important role in the treatment of CLL/SLL. Although venetoclax monotherapy is approved (ex-C...

Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab

Allison Bock, Lei Feng, Ayushi Chauhan et al. Nov 03, 2025 pp. 3739-3739 10.1182/blood-2025-3739

Abstract Introduction: Epcoritamab (epco) is a bispecific antibody (BsAb) that is FDA approved for patients (pts) with R/R LBCLs based on the...

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after BTK inhibitor era

Weihao Chen, Yuting Yan, Ying Yu et al. Nov 03, 2025 pp. 3593-3593 10.1182/blood-2025-3593

Abstract Background Waldenström's macroglobulinemia (WM) is an indolent B-cell lymphoma with high heterogeneity. Several clinical risk models...

Novel single red blood cell lifespan measurement assay through glycated hemoglobin assessment by flow cytometry

Nicolas Hebert, Elisa Domingues - Hamdi, Nassima Djouder et al. Nov 03, 2025 pp. 2897-2897 10.1182/blood-2025-2897

Abstract Introduction: Hemolysis is defined as an imbalance between the rate of red blood cell (RBC) production and destruction, leading to...

Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial

Amer Zeidan, Valeria Santini, Maria Diez-Campelo et al. Nov 03, 2025 pp. 490-490 10.1182/blood-2025-490

Abstract Introduction: IME is a first-in-class, direct, and competitive telomerase inhibitor approved for the treatment (tx) of certain adul...

Diagnostic accuracy of PET/CT scan in differentiating malignant and bland thrombi in cancer patients: A systematic review

Basant Eltaher, Amir Mahmoud, Kavya Balusu et al. Nov 03, 2025 pp. 4908-4908 10.1182/blood-2025-4908

Abstract Introduction: Differentiating between tumor thrombus and bland thrombus can be challenging, however it is of paramount importance a...

Effectiveness of polatuzumab-based regimens among elderly patients with previously untreated diffuse large B-cell lymphoma: A systematic review and meta-analysis

Zhao Peiqi, Yunyue Ju, Yukun Lan et al. Nov 03, 2025 pp. 8098-8098 10.1182/blood-2025-8098

Abstract Background Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma and disprop...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page